

Epigenetics Market by Product & Service (Enzymes, Kits & Reagents (Antibodies), Software), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR), Application (Oncology, Immunology, Developmental Biology), End User - Global Forecast to 2030

Market Report | 2025-08-15 | 491 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global epigenetics market size is projected to reach USD 4.29 billion by 2030 from USD 2.24 billion in 2025, at a CAGR of 13.9% during the forecast period. Factors such as declining sequencing costs and time, along with technological advancements in epigenetics, and a growing demand for epigenetic drugs and diagnostics drive market growth; however, limited applications of epigenomic data in toxicology, along with data privacy and security concerns, restrain market expansion.

<https://www.marketsandmarkets.com/Images/epigenetics-technologies-market-Overview.webp>

"The PCR & qPCR market is likely to grow at a faster pace."

The global epigenetics market is categorized by technology into next-generation sequencing (NGS), polymerase chain reaction (PCR) & quantitative PCR (qPCR), mass spectrometry, sonication, and other methodologies. Notably, the PCR & qPCR segment is projected to exhibit significant compound annual growth rate (CAGR). The rising utilization of methylation-specific PCR techniques enhances the sensitivity and specificity of detecting epigenetic modifications, which is anticipated to drive growth in this segment.

"DNA methylation dominated the method segment."

The epigenetics market is categorized by methodology into several segments, primarily DNA methylation, histone modifications, and other techniques. In 2024, DNA methylation dominated the market, primarily due to its established efficacy in cancer research applications. Furthermore, alternative methodologies-including non-coding RNA analysis and chromatin remodeling-are

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

anticipated to exhibit the highest CAGR throughout the forecast period. This is driven by an increasing focus on innovative epigenetic mechanisms and their prospective roles in diagnostics and therapeutic development.

"Asia Pacific region is estimated to show fastest growth rate."

On the basis of region, the flow cytometry market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, North America accounted for the major share of the epigenetics market. The Asia Pacific region is projected to experience strong growth during the forecast period, fueled by ongoing improvements in healthcare infrastructure across emerging economies. This market is further boosted by strategic collaborations, partnerships, expansions, and agreements initiated by regional industry players.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%

-□By Designation: Managers- 45%, CXOs and Directors- 30%, and Executives- 25%

-□By Region: North America -35%, Europe - 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%

List of Companies Profiled in the Report:

-□Thermo Fisher Scientific Inc. (US)

-□Merck KGaA (Germany)

-□Illumina, Inc. (US)

-□PacBio (US)

-□Danaher (US)

-□Active Motif, Inc. (US)

-□Bio-Rad Laboratories Inc. (US)

-□Promega Corporation (US)

-□Revvity (US)

-□Qiagen (Germany)

-□New England Biolabs (US)

-□Zymo Research Corporation (US)

-□Hologic Diagenode (US)

-□F. Hoffmann-La Roche Ltd. (Switzerland)

-□EpiGentek Group Inc. (US)

Research Coverage:

This research report categorizes epigenetics market by offering (kits & reagents, enzymes, instruments & accessories, software, and services), method (DNA methylation, Histone modification, and other methods), technology (NGS, PCR & qPCR, mass spectrometry, sonication, and other technologies), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, and other applications), end user for product (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), end user for service (academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report's scope includes detailed information about the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, solutions, and services; key strategies; new product and service launches, acquisitions, and recent developments related to the epigenetics market. This report also covers the competitive analysis of upcoming startups in the epigenetics industry ecosystem.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing estimates of revenue for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key Drivers (declining sequencing costs & time, expansion of population screening programs, technological advancements in epigenetics research, and rising demand for epigenetic drugs & epigenetics-based diagnostics), restraints (limited applications of epigenomic data in toxicology and data privacy concerns and security issues), opportunities (emerging applications of epigenetics and integration of multi-omics), and challenges (concerns regarding quality of antibodies and challenges associated with epigenetic editing) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the epigenetics market.
- Market Development: The report provides comprehensive information about lucrative markets and analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), among others offering products and services for epigenetics market. Other companies include EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), among others, for the epigenetics market.

Table of Contents:

1	INTRODUCTION	42
1.1	STUDY OBJECTIVES	42
1.2	MARKET DEFINITION	42
1.3	STUDY SCOPE	43
1.3.1	MARKET SEGMENTATION AND REGIONAL SCOPE	43
1.3.2	INCLUSIONS AND EXCLUSIONS	44
1.3.3	YEARS CONSIDERED	44
1.4	CURRENCY CONSIDERED	45
1.5	STAKEHOLDERS	45
1.6	SUMMARY OF CHANGES	45
2	RESEARCH METHODOLOGY	47
2.1	RESEARCH DATA	47
2.1.1	SECONDARY DATA	48
2.1.2	PRIMARY DATA	49
2.2	MARKET SIZE ESTIMATION	50
2.2.1	GLOBAL MARKET SIZE ESTIMATION	50
2.2.2	INSIGHTS FROM PRIMARY EXPERTS	53
2.2.3	SEGMENTAL MARKET ASSESSMENT	53
2.3	GROWTH FORECAST MODEL	55
2.4	DATA TRIANGULATION	57
2.5	RESEARCH ASSUMPTIONS	58
2.6	RESEARCH LIMITATIONS	59
2.7	RISK ANALYSIS	59
3	EXECUTIVE SUMMARY	60
4	PREMIUM INSIGHTS	65
4.1	EPIGENETICS MARKET OVERVIEW	65
4.2	NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY	66

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.3	EPIGENETICS PRODUCT MARKET, BY END USER, 2024	66
4.4	EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	67
5	MARKET OVERVIEW	68
5.1	INTRODUCTION	68
5.2	MARKET DYNAMICS	68
5.2.1	DRIVERS	69
5.2.1.1	Declining sequencing costs and time	69
5.2.1.2	Growing emphasis on population-scale screening initiatives	71
5.2.1.3	Technological advancements in epigenetics research	71
5.2.1.4	Rising demand for epigenetic drugs and epigenetic-based therapeutics	72
5.2.2	RESTRAINTS	73
5.2.2.1	Limited applications of epigenomic data in toxicology	73
5.2.2.2	Data privacy concerns and security issues	74
5.2.3	OPPORTUNITIES	74
5.2.3.1	Emerging applications of epigenetics	74
5.2.3.2	Integration of multi-omics	75
5.2.4	CHALLENGES	75
5.2.4.1	Concerns regarding quality of antibodies	75
5.2.4.2	Challenges associated with epigenetic editing	76
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	76
5.4	PRICING ANALYSIS	77
5.4.1	AVERAGE SELLING PRICE TREND, BY KEY PLAYER	77
5.4.2	AVERAGE SELLING PRICE TREND, BY REGION	80
5.5	VALUE CHAIN ANALYSIS	82
5.6	ECOSYSTEM ANALYSIS	84
5.7	INVESTMENT AND FUNDING SCENARIO	87
5.8	TECHNOLOGY ANALYSIS	89
5.8.1	KEY TECHNOLOGIES	89
5.8.1.1	Single-cell sequencing	89
5.8.1.2	Chromatin immunoprecipitation	89
5.8.2	COMPLEMENTARY TECHNOLOGIES	89
5.8.2.1	DNA methylation microarrays	89
5.8.2.2	CRISPR-based genome editing	89
5.9	PATENT ANALYSIS	90
5.10	TRADE DATA ANALYSIS	92
5.10.1	IMPORT DATA	93
5.10.2	EXPORT DATA	94
5.11	KEY CONFERENCES AND EVENTS, 2025-2026	96
5.12	TARIFF AND REGULATORY LANDSCAPE	97
5.12.1	TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00	97
5.12.2	REGULATORY FRAMEWORK	98
5.12.3	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	100
5.13	PORTER'S FIVE FORCES ANALYSIS	103
5.13.1	BARGAINING POWER OF SUPPLIERS	104
5.13.2	BARGAINING POWER OF BUYERS	104
5.13.3	THREAT OF NEW ENTRANTS	105
5.13.4	THREAT OF SUBSTITUTES	105

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.13.5	INTENSITY OF COMPETITIVE RIVALRY	105
5.14	KEY STAKEHOLDERS AND BUYING CRITERIA	105
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	106
5.14.2	KEY BUYING CRITERIA	107
5.15	IMPACT OF AI/GEN AI ON EPIGENETICS MARKET	108
5.15.1	INTRODUCTION	108
5.15.2	MARKET POTENTIAL OF AI IN EPIGENETICS	108
5.15.3	AI USE CASES	108
5.15.4	KEY COMPANIES IMPLEMENTING AI/GEN AI	109
5.15.5	FUTURE OF AI/GEN AI IN EPIGENETICS MARKET	109
5.16	IMPACT OF 2025 US TARIFF	110
5.16.1	INTRODUCTION	110
5.16.2	KEY TARIFF RATES	110
5.16.3	PRICE IMPACT ANALYSIS	113
5.16.4	KEY IMPACTS ON VARIOUS REGIONS	114
5.16.4.1	US	114
5.16.4.2	Europe	114
5.16.4.3	Asia Pacific	114
5.16.5	END-USE INDUSTRY IMPACT	115
5.16.5.1	Pharmaceutical and biotech companies	115
5.16.5.2	Contract Research Organizations (CROs)	115
5.16.5.3	Academic and research institutes	115
6	EPIGENETICS MARKET, BY OFFERING	116
6.1	INTRODUCTION	117
6.2	KITS & REAGENTS	118
6.2.1	ANTIBODIES	122
6.2.1.1	Growing demand for recombinant antibodies for detection of epigenetic targets to propel market	122
6.2.2	CHIP-SEQUENCING KITS & REAGENTS	125
6.2.2.1	Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market	125
6.2.3	BISULFITE CONVERSION KITS & REAGENTS	129
6.2.3.1	Effective outcomes associated with bisulfite conversion to sustain growth	129
6.2.4	WHOLE-GENOME AMPLIFICATION KITS & REAGENTS	132
6.2.4.1	Ability to maintain relative proportions of genes in original pool to stimulate growth	132
6.2.5	5-HMC & 5-MC ANALYSIS KITS & REAGENTS	136
6.2.5.1	Introduction of unique kits for 5-mC and 5-hmC analysis to support growth	136
6.2.6	HISTONES	139
6.2.6.1	Emerging importance of chromatin-associated proteins and histones in epigenetic research to bolster growth	139
6.2.7	OTHER KITS & REAGENTS	143
6.3	ENZYMES	147
6.3.1	DNA-MODIFYING ENZYMES	150
6.3.1.1	Broadening applications of DNA methylation to facilitate growth	150
6.3.2	PROTEIN-MODIFYING ENZYMES	154
6.3.2.1	Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to spur growth	154
6.3.3	OTHER ENZYMES	157
6.4	INSTRUMENTS & ACCESSORIES	160
6.4.1	WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO EXPEDITE GROWTH	160
6.5	SOFTWARE	164

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.5.1	DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROMOTE GROWTH	164
6.6	SERVICES	167
6.6.1	EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE MARKET	167
7	EPIGENETICS MARKET, BY TECHNOLOGY	171
7.1	INTRODUCTION	172
7.2	NEXT-GENERATION SEQUENCING (NGS)	172
7.2.1	INCREASING LAUNCHES OF NEXT-GENERATION SEQUENCING PLATFORMS TO FACILITATE GROWTH	172
7.3	PCR & QPCR	177
7.3.1	RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET	177
7.4	MASS SPECTROMETRY	181
7.4.1	GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET	181
7.5	SONICATION	185
7.5.1	RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO EXPEDITE GROWTH	185
7.6	OTHER TECHNOLOGIES	188
8	EPIGENETICS MARKET, BY METHOD	192
8.1	INTRODUCTION	193
8.2	DNA METHYLATION	193
8.2.1	INCREASING RESEARCH & DEVELOPMENT ACTIVITIES TO SPUR GROWTH	193
8.3	HISTONE MODIFICATIONS	197
8.3.1	GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET	197
8.4	OTHER METHODS	201
9	EPIGENETICS MARKET, BY APPLICATION	204
9.1	INTRODUCTION	205
9.2	ONCOLOGY	205
9.2.1	GROWING INVESTMENT IN EPIGENETIC-BASED RESEARCH TO BOOST MARKET	205
9.3	METABOLIC DISEASES	211
9.3.1	EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR GROWTH	211
9.4	IMMUNOLOGY	214
9.4.1	GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE MARKET	214
9.5	DEVELOPMENTAL BIOLOGY	218
9.5.1	INCREASING RESEARCH ON CELL GROWTH AND DIFFERENTIATION TO PROPEL MARKET	218
9.6	CARDIOVASCULAR DISEASES	221
9.6.1	EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO AID GROWTH	221
9.7	OTHER APPLICATIONS	225
10	EPIGENETICS PRODUCTS MARKET, BY END USER	229
10.1	INTRODUCTION	230
10.2	ACADEMIC & RESEARCH INSTITUTES	230
10.2.1	INCREASING PUBLIC-PRIVATE COLLABORATIONS TO FAVOR GROWTH	230
10.3	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	234
10.3.1	GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETIC-BASED DRUGS TO FUEL MARKET	234
10.4	HOSPITALS & CLINICS	238
10.4.1	GROWING USE OF PERSONALIZED MEDICINE TO PROPEL MARKET	238
10.5	CONTRACT RESEARCH ORGANIZATIONS	242
10.5.1	INCREASING DEMAND FOR SCALABLE, HIGH-THROUGHPUT EPIGENETICS KITS TO PROMOTE GROWTH	242
11	EPIGENETICS SERVICE MARKET, BY END USER	246

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1	INTRODUCTION	247
11.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	247
11.2.1	RISING DEMAND FOR THERAPEUTIC DISCOVERIES TO BOLSTER GROWTH	247
11.3	ACADEMIC & RESEARCH INSTITUTES	251
11.3.1	INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH	251
11.4	HOSPITALS & CLINICS	254
11.4.1	INCREASING INTEGRATION OF EPIGENETIC ASSAYS INTO CLINICAL DIAGNOSTICS, PROGNOSTICS, AND PERSONALIZED MEDICINE TO AID GROWTH	254
	?	
12	EPIGENETICS MARKET, BY REGION	258
12.1	INTRODUCTION	259
12.2	NORTH AMERICA	259
12.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	259
12.2.2	US	266
12.2.2.1	Strong network of well-established epigenetic product manufacturers to spur growth	266
12.2.3	CANADA	270
12.2.3.1	Favorable government initiatives to contribute to growth	270
12.3	EUROPE	275
12.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	275
12.3.2	GERMANY	281
12.3.2.1	Significant investments in next-generation sequencing to bolster growth	281
12.3.3	UK	285
12.3.3.1	Rising acceptance of genome-based diagnostic techniques to support growth	285
12.3.4	FRANCE	290
12.3.4.1	Growing demand for PCR technologies to drive market	290
12.3.5	ITALY	295
12.3.5.1	High incidence of cancer to expedite growth	295
12.3.6	SPAIN	300
12.3.6.1	Well-established network of research centers and universities to boost market	300
12.3.7	REST OF EUROPE	304
12.4	ASIA PACIFIC	308
12.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	308
12.4.2	CHINA	315
12.4.2.1	High demand for personalized medicine to accelerate growth	315
12.4.3	JAPAN	320
12.4.3.1	Increasing collaborations between research & academic organizations to favor growth	320
12.4.4	INDIA	325
12.4.4.1	Expanding base of biotechnology facilities to drive market	325
12.4.5	AUSTRALIA	330
12.4.5.1	Growing hub for epigenetics to propel market	330
12.4.6	SOUTH KOREA	334
12.4.6.1	Rising burden of chronic diseases to foster growth	334
12.4.7	REST OF ASIA PACIFIC	338
	?	
12.5	LATIN AMERICA	342
12.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	342
12.5.2	BRAZIL	347

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.5.2.1	Increasing number of healthcare providers incorporating epigenetic testing to aid growth	347
12.5.3	MEXICO	351
12.5.3.1	Growing adoption of cutting-edge technologies to drive market	351
12.5.4	REST OF LATIN AMERICA	355
12.6	MIDDLE EAST	359
12.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST	359
12.6.2	GCC COUNTRIES	365
12.6.2.1	Saudi Arabia	370
12.6.2.1.1	Growing healthcare expenditure to propel market	370
12.6.2.2	UAE	375
12.6.2.2.1	Increasing collaborations between public and private sectors to spur growth	375
12.6.2.3	Rest of GCC countries	379
12.6.3	REST OF MIDDLE EAST	383
12.7	AFRICA	387
12.7.1	RISING DEMAND FOR TARGETED THERAPIES TO AUGMENT GROWTH	387
12.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	387
13	COMPETITIVE LANDSCAPE	393
13.1	INTRODUCTION	393
13.2	KEY PLAYER STRATEGIES	393
13.3	REVENUE ANALYSIS	395
13.4	MARKET SHARE ANALYSIS	395
13.5	COMPANY VALUATION AND FINANCIAL METRICS	398
13.6	BRAND/PRODUCT COMPARISON	399
13.6.1	THERMO FISHER SCIENTIFIC INC.	399
13.6.2	ILLUMINA, INC.	399
13.6.3	MERCK KGAA	400
13.6.4	DANAHER	400
13.7	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	400
13.7.1	STARS	400
13.7.2	EMERGING LEADERS	400
13.7.3	PERVASIVE PLAYERS	400
13.7.4	PARTICIPANTS	401
13.7.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	402
13.7.5.1	Company footprint	402
13.7.5.2	Region footprint	403
13.7.5.3	Offering footprint	403
13.7.5.4	Method footprint	404
13.7.5.5	Technology footprint	405
13.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	406
13.8.1	PROGRESSIVE COMPANIES	406
13.8.2	RESPONSIVE COMPANIES	406
13.8.3	DYNAMIC COMPANIES	406
13.8.4	STARTING BLOCKS	406
13.8.5	COMPETITIVE BENCHMARKING	408
13.8.5.1	Detailed list of key startups/SMEs	408
13.8.5.2	Competitive benchmarking of key startups/SMEs	409
13.9	COMPETITIVE SCENARIO	409

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.9.1 PRODUCT LAUNCHES 409
- 13.9.2 DEALS 411
- 13.9.3 EXPANSIONS 412
- 14 COMPANY PROFILES 413
- 14.1 KEY MARKET PLAYERS 413
 - 14.1.1 THERMO FISHER SCIENTIFIC INC. 413
 - 14.1.1.1 Business overview 413
 - 14.1.1.2 Products offered 414
 - 14.1.1.3 Recent developments 416
 - 14.1.1.3.1 Product launches 416
 - 14.1.1.3.2 Deals 417
 - 14.1.1.4 MnM view 417
 - 14.1.1.4.1 Key strengths 417
 - 14.1.1.4.2 Strategic choices 417
 - 14.1.1.4.3 Weaknesses and competitive threats 417
 - 14.1.2 ILLUMINA, INC. 418
 - 14.1.2.1 Business overview 418
 - 14.1.2.2 Products offered 419
 - 14.1.2.3 Recent developments 421
 - 14.1.2.3.1 Product launches 421
 - 14.1.2.3.2 Deals 421
 - 14.1.2.4 MnM view 422
 - 14.1.2.4.1 Key strengths 422
 - 14.1.2.4.2 Strategic choices 422
 - 14.1.2.4.3 Weaknesses and competitive threats 422
 - 14.1.3 MERCK KGAA 423
 - 14.1.3.1 Business overview 423
 - 14.1.3.2 Products offered 424
 - 14.1.3.3 MnM view 426
 - 14.1.3.3.1 Key strengths 426
 - 14.1.3.3.2 Strategic choices 426
 - 14.1.3.3.3 Weaknesses and competitive threats 426
 - 14.1.4 PACBIO 427
 - 14.1.4.1 Business overview 427
 - 14.1.4.2 Products offered 428
 - 14.1.4.3 Recent developments 429
 - 14.1.4.3.1 Product launches 429
 - 14.1.4.3.2 Deals 430
 - 14.1.4.3.3 Expansions 430
 - 14.1.4.4 MnM view 431
 - 14.1.4.4.1 Key strengths 431
 - 14.1.4.4.2 Strategic choices 431
 - 14.1.4.4.3 Weaknesses and competitive threats 431
 - 14.1.5 DANAHER 432
 - 14.1.5.1 Business overview 432
 - 14.1.5.2 Products offered 433
 - 14.1.5.3 Recent developments 435

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.5.3.1	Deals	435
14.1.5.4	MnM view	435
14.1.5.4.1	Key strengths	435
14.1.5.4.2	Strategic choices	435
14.1.5.4.3	Weaknesses and competitive threats	435
14.1.6	BIO-RAD LABORATORIES, INC.	436
14.1.6.1	Business overview	436
14.1.6.2	Products offered	437
14.1.7	ACTIVE MOTIF	441
14.1.7.1	Business overview	441
14.1.7.2	Products offered	441
14.1.7.3	Recent developments	444
14.1.7.3.1	Deals	444
14.1.8	NEW ENGLAND BIOLABS	445
14.1.8.1	Business overview	445
14.1.8.2	Products offered	445
14.1.8.3	Recent developments	447
14.1.8.3.1	Product launches	447
14.1.8.3.2	Deals	448
14.1.9	QIAGEN	449
14.1.9.1	Business overview	449
14.1.9.2	Products offered	450
14.1.9.3	Recent developments	451
14.1.9.3.1	Product launches	451
	?	
14.1.10	ZYMO RESEARCH CORPORATION	452
14.1.10.1	Business overview	452
14.1.10.2	Products offered	452
14.1.10.3	Recent developments	455
14.1.10.3.1	Product launches	455
14.1.10.3.2	Expansions	455
14.1.10.3.3	Other developments	455
14.1.11	REVVITY	456
14.1.11.1	Business overview	456
14.1.11.2	Products offered	457
14.1.11.3	Recent developments	458
14.1.11.3.1	Deals	458
14.1.12	HOLOGIC, INC.	459
14.1.12.1	Business overview	459
14.1.12.2	Products offered	460
14.1.13	F. HOFFMANN-LA ROCHE LTD	463
14.1.13.1	Business overview	463
14.1.13.2	Products offered	464
14.1.14	PROMEGA CORPORATION	466
14.1.14.1	Business overview	466
14.1.14.2	Products offered	466
14.1.15	EPIGENTEK GROUP INC.	468

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.15.1	Business overview	468
14.1.15.2	Products offered	468
14.2	OTHER PLAYERS	472
14.2.1	EPICYpher	472
14.2.2	FIOS GENOMICS	473
14.2.3	GENOMESCAN	474
14.2.4	CREATIVE BIOGENE	475
14.2.5	BPS BIOSCIENCE, INC.	475
14.2.6	ABNOVA CORPORATION	477
14.2.7	CREATIVE DIAGNOSTICS	478
14.2.8	BIOMODAL	479
14.2.9	INTEGRATED DNA TECHNOLOGIES, INC.	480
14.2.10	NOVOGENE CO., LTD.	481
	?	
15	APPENDIX	482
15.1	DISCUSSION GUIDE	482
15.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	487
15.3	CUSTOMIZATION OPTIONS	489
15.4	RELATED REPORTS	489
15.5	AUTHOR DETAILS	490

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Epigenetics Market by Product & Service (Enzymes, Kits & Reagents (Antibodies), Software), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR), Application (Oncology, Immunology, Developmental Biology), End User - Global Forecast to 2030

Market Report | 2025-08-15 | 491 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature